Century Therapeutics exec sells shares for tax withholding

Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 479 shares of common stock on March 9, 2026 at $2.536 per share.

Rhea-AI Filing Summary

Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 479 shares of common stock on March 9, 2026 at $2.536 per share. According to the footnote, this sale was executed solely to cover tax withholding obligations related to vesting restricted stock units and was not at his discretion.

After the transaction, Russotti directly held 525,503 common shares and also had an indirect holding of 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing therefore reflects a routine tax-related sale while maintaining a substantial ongoing equity position.

Insider Trade Summary

Net Seller: 479 shares

Net Sell 2 txns

Insider Russotti Gregory

Role See Remarks

Sold 479 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock	479	$2.536	$1K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 525,503 shares (Direct); Common Stock — 92,773 shares (Indirect, By Gregory Russotti 2021 Family Trust)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Century Therapeutics (IPSC) officer Gregory Russotti report in this Form 4?

Gregory Russotti reported an automatic sale of 479 Century Therapeutics shares. The shares were sold on March 9, 2026 at $2.536 each, and the transaction was linked to tax withholding on vesting restricted stock units rather than a discretionary open-market sale.

How many Century Therapeutics (IPSC) shares did Russotti sell and at what price?

Russotti sold 479 shares of Century Therapeutics common stock at $2.536 per share. The Form 4 describes this as an automatic sale to cover tax withholding obligations arising from restricted stock unit vesting, rather than a voluntary portfolio rebalancing or directional trade.

Why were Gregory Russotti’s Century Therapeutics (IPSC) shares sold in this transaction?

The shares were sold to cover tax withholding obligations on RSU vesting. The footnote explains that the sale was automatic, executed in connection with restricted stock units vesting, and was not carried out at the personal discretion of the reporting person.

How many Century Therapeutics (IPSC) shares does Russotti hold after this Form 4?

After the sale, Russotti directly held 525,503 shares of common stock. The filing also shows an indirect holding of 92,773 shares through the Gregory Russotti 2021 Family Trust, indicating a substantial ongoing ownership position in Century Therapeutics.

Does this Century Therapeutics (IPSC) Form 4 indicate a typical insider sale signal?

The transaction appears as a routine tax-related sale, not a typical discretionary sale. The Form 4 footnote states the shares were sold automatically to satisfy tax withholding on restricted stock unit vesting, reducing its informational value as a directional trading signal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russotti Gregory

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		479	D	$2.536	525,503	D
Common Stock								92,773	I	By Gregory Russotti 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Remarks:

Title: Chief Technology and Manufacturing Officer

	/s/ Douglas Carr, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.